Table III.
Genotypic and allelic frequencies of the MDM2 40-bp I/D polymorphism in patients with PCa and controls.
| MDM2 40-bp I/D | PCa, n (%) | Control, n (%) | OR (95% CI) | P-value |
|---|---|---|---|---|
| Codominant | ||||
| I/I | 39 (37.9) | 72 (50.7) | 1.00 | – |
| I/D | 60 (58.2) | 59 (41.6) | 1.88 (1.11–3.19) | 0.023 |
| D/D | 4 (3.9) | 11 (7.7) | 0.67 (0.20–2.25) | 0.578 |
| Dominant | ||||
| I/I | 39 (37.9) | 72 (50.7) | 1.00 | – |
| I/D+D/D | 64 (62.1) | 70 (49.3) | 1.69 (1.00–2.83) | 0.051 |
| Recessive | ||||
| I/I+I/D | 99 (96.1) | 131 (92.3) | 1.00 | – |
| D/D | 4 (3.9) | 11 (7.7) | 0.45 (0.15–1.56) | 0.284 |
| Alleles | ||||
| I | 138 (67.0) | 203 (71.5) | 1.00 | – |
| D | 68 (33.0) | 81 (28.5) | 1.23 (0.84–1.82) | 0.320 |
MDM2, murine double minute-2; I, insertion; D, deletion; PCa, prostate cancer; OR, odds ratio; CI, confidence interval.